Dr. Andy Li has more than 25 years of biomedical research and biopharmaceutical industry experience with proven track records in global drug development in multiple disciplines and therapeutic areas, including marketing, R&D project management and leadership, portfolio management and strategic planning, alliance management, and business development. He previously held various management positions with increased responsibilities at GSK, Abbott and Daiichi Sankyo. During his extensive career, Andy worked directly on and made significant contributions to several highly successful projects and products, including HUMIRA and Olmesartan. As part of the project leadership, he directly managed and led the development, registration, and commercialization efforts of these major projects/products in key markets, including the U.S., Europe, Japan, China, Korea, Taiwan, Brazil and others. In 2015, he co-founded BioSense Global LLC, which focuses on investing in the biotech/medtech space. In addition, the company licenses in and develops high-potential projects/products in China to help address unmet medical needs in that increasingly important market.
PhD from Albert Einstein College of Medicine and MBA from Duke University.
EXPERTISE: Business Development, Alliance Management, Biopharmaceutical R&D, Project and Portfolio Management, Market Entry and Access, Regulatory Affairs, Commercialization, Start-ups, Venture Investment and Financing.